
SANTA CRUZ BIOTECHNOLOGY, INC.

OR8J1 (C-12): sc-132021



BACKGROUND

With approximately 135 million base pairs and 1,400 genes, chromosome 11 makes up around 4% of human genomic DNA and is considered a gene and disease association-dense chromosome. The chromosome 11-encoded Atm gene is important for regulation of cell cycle arrest and apoptosis following double strand DNA breaks. Atm mutation leads to the disorder known as ataxia-telangiectasia. The blood disorders Sickle cell anemia and β thalassemia are caused by HBB gene mutations. Wilms' tumors, WAGR syndrome and Denys-Drash syndrome are associated with mutations of the WT1 gene. Jervell and Lange-Nielsen syndrome, Jacobsen syndrome are also associated with defects in chromosome 11. The OR8J1 gene product has been provisionally designated OR8J1 pending further characterization.

REFERENCES

- Grossfeld, P.D., et al. 2004. The 11q terminal deletion disorder: a prospective study of 110 cases. Am. J. Med. Genet. A 129: 51-61.
- Loussouarn, G., et al. 2006. KCNQ1 K⁺ channel-mediated cardiac channelopathies. Methods Mol. Biol. 337: 167-183.
- 3. Taylor, T.D., et al. 2006. Human chromosome 11 DNA sequence and analysis including novel gene identification. Nature 440: 497-500.
- Zehelein, J., et al. 2006. Skipping of exon 1 in the KCNQ1 gene causes Jervell and Lange-Nielsen syndrome. J. Biol. Chem. 281: 35397-35403.
- 5. Ataga, K.I., et al. 2007. β -thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br. J. Haematol. 139: 3-13.
- Berger, A.C., et al. 2007. The subcellular localization of the Niemann-Pick type C proteins depends on the adaptor complex AP-3. J. Cell Sci. 120: 3640-3652.
- Lee, J.H. and Paull, T.T. 2007. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26: 7741-7748.
- 8. O'Connor, M.J., et al. 2007. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26: 7816-7824.
- 9. Kaste, S.C., et al. 2008. Wilms' tumour: prognostic factors, staging, therapy and late effects. Pediatr. Radiol. 38: 2-17.

CHROMOSOMAL LOCATION

Genetic locus: OR8J1 (human) mapping to 11q12.1.

SOURCE

OR8J1 (C-12) is an affinity purified goat polyclonal antibody raised against a peptide mapping within a C-terminal cytoplasmic domain of OR8J1 of human origin.

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-132021 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

OR8J1 (C-12) is recommended for detection of OR8J1 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with other OR8 family members.

Suitable for use as control antibody for OR8J1 siRNA (h): sc-96915, OR8J1 shRNA Plasmid (h): sc-96915-SH and OR8J1 shRNA (h) Lentiviral Particles: sc-96915-V.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.